QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Neurology

• Publication date

  2016-02-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-016-8058-7PMID 26914926
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breast tomosynthesis.

  2019cited by this paper
• Added Value of Contrast‐Enhanced Spectral Mammography in Postscreening Assessment

  2016cited by this paper
• Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening.

  2016cited by this paper
• Contrast-enhanced dual energy mammography with a novel anode/filter combination and artifact reduction: a feasibility study

  2016cited by this paper
• Diagnostic performance of contrast-enhanced spectral mammography: Systematic review and meta-analysis.

  2016cited by this paper
• Digital Compared with Screen-Film Mammography: Measures of Diagnostic Accuracy among Women Screened in the Ontario Breast Screening Program.

  2016cited by this paper
• Contrast-enhanced spectral mammography improves diagnostic accuracy in the symptomatic setting.

  2016cited by this paper
• Digital breast tomosynthesis (3D-mammography) screening: data and implications for population screening

  2015cited by this paper
• Review of radiation dose estimates in digital breast tomosynthesis relative to those in two-view full-field digital mammography.

  2015cited by this paper
• Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study

  2015cited by this paper
• Breast-cancer screening--viewpoint of the IARC Working Group.

  2015influential reference
• Breast MRI: EUSOBI recommendations for women’s information

  2015influential reference
• Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients

  2015cited by this paper
• Effect of treatment and mammography detection on breast cancer survival over time: 1990‐2007

  2015cited by this paper
• A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

  2014influential reference
• Patient expectations and experiences of multiple sclerosis interferon β-1a treatment: a longitudinal, observational study in routine UK clinical practice

  2014cited by this paper
• Contrast-enhanced spectral mammography: Does mammography provide additional clinical benefits or can some radiation exposure be avoided?

  2014cited by this paper
• Screening mammography benefit controversies: sorting the evidence.

  2014cited by this paper
• Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme

  2014cited by this paper
• Symptoms and Association with Health Outcomes in Relapsing-Remitting Multiple Sclerosis: Results of a US Patient Survey

  2014cited by this paper
• Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images.

  2014cited by this paper
• The risk of radiation-induced breast cancers due to biennial mammographic screening in women aged 50–69 years is minimal

  2014cited by this paper
• Radiation Exposure of Contrast-Enhanced Spectral Mammography Compared With Full-Field Digital Mammography

  2014cited by this paper
• Interval breast cancers: absolute and proportional incidence and blinded review in a community mammographic screening program.

  2014cited by this paper
• Mammography interval and breast cancer mortality in women over the age of 75

  2014cited by this paper
• European Breast Cancer Service Screening Outcomes: A First Balance Sheet of the Benefits and Harms

  2014cited by this paper
• Digital breast tomosynthesis from concept to clinical care.

  2014cited by this paper
• Patient expectations and experiences of multiple sclerosis interferon β -1a treatment: a longitudinal, observational study in routine UK clinical practice

  2014cited by this paper
• European guidelines for quality assurance in breast cancer screening and diagnosis

  2013cited by this paper
• Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors

  2013cited by this paper
• Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study.

  2013cited by this paper
• Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma.

  2013cited by this paper
• Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program.

  2013cited by this paper
• Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size

  2013cited by this paper
• Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration

  2013cited by this paper
• Risk of radiation-induced breast cancer from mammographic screening.

  2011cited by this paper
• Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

  2011influential reference
• Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines

  2011cited by this paper
• Mammography: EUSOBI recommendations for women’s information

  2011cited by this paper
• Improving quality of life in multiple sclerosis: an unmet need.

  2011cited by this paper
• A pooled analysis of interval cancer rates in six European countries

  2010cited by this paper
• Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis

  2010cited by this paper
• Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

  2010cited by this paper
• The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue

  2009cited by this paper
• Multiple sclerosis beyond EDSS: depression and fatigue.

  2009cited by this paper
• Therapieadhärenz in der neurologischen Praxis

  2008cited by this paper
• Reducing the risk of iodine-based and MRI contrast media administration: recommendation for a questionnaire at the time of booking.

  2008cited by this paper
• [Adherence to neurologic treatment. Lessons from multiple sclerosis].

  2008cited by this paper
• Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

  2008cited by this paper
• Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review.

  2007cited by this paper
• Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Ein neuropsychologisches Screening zur Erfassung kognitiver Störungen bei MS-Patienten - Das Multiple Sklerose Inventarium Cognition (MUSIC)

  2004cited by this paper
• Monitoring women's experiences during three rounds of breast cancer screening: results from a longitudinal study

  2002cited by this paper
• An examination of suicidal intent in patients with multiple sclerosis

  2002cited by this paper
• Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

  2001cited by this paper
• Diagnostic criteria for multiple sclerosis.

  2001cited by this paper
• Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment

  1996cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

  1995cited by this paper
• Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

  1995cited by this paper
• Allgemeine Depressions Skala

  1993cited by this paper
• Symptomatic fatigue in multiple sclerosis.

  1984cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• A Review of the Impact of Platform Therapies (DMTs) on Associated Clinical Symptoms of Multiple Sclerosis

  2025influential citation
• Therapeutic options and outcomes in pediatric-onset multiple sclerosis with a focus on fingolimod—Eastern European tertiary center experience and literature review

  2025cites this paper
• Glatiramer Acetate Modifies the Immune Profiles of Monocyte-Derived Dendritic Cells In Vitro Without Affecting Their Generation

  2025cites this paper
• Quality of reporting health behaviors for multiple sclerosis (QuoRH‐MS): A scoping review to inform intervention planning and improve consistency of reporting

  2024cites this paper
• An overview on disease modifying and symptomatic drug treatments for multiple sclerosis

  2024cites this paper
• A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis.

  2024cites this paper
• Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review

  2023cites this paper
• Copolímero-1 como terapia potencial para el deterioro cognitivo leve

  2023cites this paper
• The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review

  2023cites this paper
• Fatigue in multiple sclerosis: A UK MS-register based study.

  2022cites this paper
• Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice.

  2022cites this paper
• Copolymer-1 as a potential therapy for mild cognitive impairment.

  2022cites this paper
• Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation

  2022cites this paper
• Glatiramer acetate attenuates depressive/anxiety-like behaviors and cognitive deficits induced by post-weaning social isolation in male mice

  2021cites this paper
• The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review

  2021cites this paper
• Long-term drug treatment in multiple sclerosis: safety success and concerns

  2020cites this paper
• Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review

  2020cites this paper
• Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate

  2019cites this paper
• Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

  2019cites this paper
• Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

  2019cites this paper
• Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.

  2019cites this paper
• Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis

  2018cites this paper
• Two decades of glatiramer acetate: From initial discovery to the current development of generics.

  2017cites this paper
• A Potential Life-Threatening Reaction to Glatiramer Acetate in Rett Syndrome.

  2017cites this paper
• Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

  2017cites this paper
• Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

  2017cites this paper
• Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery

  2017cites this paper
• Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis

  2016influential citation
• Drugs that Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs

  2015cites this paper